RecruitingGlioblastoma

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Eligible age

18+ yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S

Sponsor: Patrick Wen, MD

You may qualify if…

✓ Participants must have histologically confirmed intracranial glioblastoma or gliosarcoma following maximum surgical resection. Tumors primarily localized in the infratentorial compartment will be excluded.
✓ Participants may have had prior surgery for glioblastoma or gliosarcoma but no systemic or radiation therapy.
✓ Age ≥ 18 years.
✓ Karnofsky performance status ≥60
✓ Participants must have normal organ and marrow function as defined below:
✓ Leukocytes ≥3,000/mL
✓ Absolute neutrophil count ≥1,500/mL
✓ Platelets ≥100,000/mL

You may not qualify if…

✕ Participants will not be eligible if the original diagnosis was a lower grade glioma and a subsequent histologic diagnosis revealed glioblastoma.
✕ Planned major surgery.
✕ Participants who are receiving any other investigational agents.
✕ Participants who have had any prior cranial radiotherapy.
✕ Planned use of Optune™.
✕ History of a different malignancy, unless (a) have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy, and/or (b) malignancy was cervical cancer in situ, superficial bladder cancer or basal cell or squamous cell carcinoma of the skin, and malignancy has been treated. Patients who meet the above listed criteria and are only on preventative treatment will be deemed eligible.
✕ History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician.
✕ Impaired cardiac function or clinically significant cardiac diseases, including any of the following: